Supporting particle investigations with risk-based decision-making
Broadcast dateWed, Nov 30, 2022
- Valerie Rautureau - Eli LillyMarcel Uijlen - OrganonAntonio Burazer - TakedaScott Ewan - BioPhorum
The presence of visible particles in parenteral medicines is a perennial issue for the industry.
How do companies manage particles when they are found, especially when atypical in nature?
What can companies do to assess the risk of a particle, and how can a particle impact the future of a batch of a biopharmaceutical product?